The exclusion of dead bacterial cells is essential for accurate molecular analysis of clinical samples

Geraint Rogers, Peter Marsh, Franziska Stressmann, Collette Allen, Thomas Daniels, Mary Carroll, Kenneth Bruce

    Research output: Contribution to journalArticle

    43 Citations (Scopus)

    Abstract

    The DNA-based techniques used to detect bacteria in clinical samples are unable to discriminate between live bacteria, dead bacteria, and extracellular DNA. This failure to limit analysis to viable bacterial cells represents a significant problem, leading to false-positive results, as well as a failure to resolve the impact of antimicrobial therapy. The use of propidium monoazide treatment significantly reduces the contribution of dead cells and extracellular DNA to such culture-independent analyses. Here, the increased ability to resolve the impact of antibiotic therapy on Pseudomonas aeruginosa load in cystic fibrosis respiratory samples reveals statistically significant changes that would otherwise go undetected.

    Original languageEnglish
    Pages (from-to)1656-1658
    Number of pages3
    JournalCLINICAL MICROBIOLOGY AND INFECTION
    Volume16
    Issue number11
    DOIs
    Publication statusPublished - Nov 2010

    Keywords

    • Antibiotic treatment
    • Bacterial viability
    • Cystic fibrosis
    • Propidium monoazide
    • Q-PCR

    Fingerprint Dive into the research topics of 'The exclusion of dead bacterial cells is essential for accurate molecular analysis of clinical samples'. Together they form a unique fingerprint.

  • Cite this